Birtamimab is a Monoclonal Antibody owned by Prothena Corp, and is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing.

Birtamimab is a amyloid protein inhibitor monoclonal antibody. It inhibits the circulating soluble and deposited aggregated amyloid that accumulate in patients with AL amyloidosis. Proliferating B-cells in dyscrasia produce an excess of immunoglobulin light chain. These can form toxic aggregates, ultimately leading to abnormal AL protein deposition and organ dysfunction present in primary (AL) amyloidosis. Antibodies specifically target the amyloid that accumulates in both AL and AA forms of amyloidosis and check the progression of primary (AL) and secondary (AA) systemic amyloidosis. The drug candidate directly neutralizes soluble toxic aggregates and promote clearance of amyloid via phagocytosis to remove organ-deposited amyloid that causes organ dysfunction in patients with AL amyloidosis.

The revenue for Birtamimab is expected to reach a total of $4.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Birtamimab NPV Report.

Birtamimab was originated by Prothena Biosciences and Prothena Therapeutics and is currently owned by Prothena Corp.

Birtamimab Overview

Birtamimab (NEO-D001) is under development for the treatment of primary systemic amyloidosis. The drug candidate is administered intravenously as powder for solution. NEOD-001 is a monoclonal antibody that targets aberrant amyloid protein. It was also under development for secondary systemic amyloidosis.

Prothena Corp Overview

Prothena Corp (Prothena) discovers and develops therapies for the treatment of neurological disorders. It is evaluating Prasinezumab (PRX002/RG7935), a monoclonal antibody targeting alpha-synuclein protein, against Parkinson’s disease and other related synucleinopathies; and PRX004, an investigational antibody to treat transthyretin amyloidosis (ATTR amyloidosis), by targeting and clearing the misfolded (toxic) forms of the TTR amyloid protein. The company is also advancing its pipeline to treat Alzheimer’s disease (AD), frontotemporal dementia and amyotrophic lateral sclerosis (ALS). Prothena works in collaboration with Roche Holding AG, Bristol Myers Squibb and other companies to develop its products. It has operations in California, the United States. Prothena is headquartered in Dublin, Ireland.

The company reported revenues of (US Dollars) US$200.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.9 million in FY2020. The operating profit of the company was US$72 million in FY2021, compared to an operating loss of US$112.7 million in FY2020. The net profit of the company was US$67 million in FY2021, compared to a net loss of US$111.1 million in FY2020. The company reported revenues of US$1.5 million for the third quarter ended September 2022, an increase of 15.6% over the previous quarter.

Quick View – Birtamimab

Report Segments
  • Innovator
Drug Name
  • Birtamimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.